Technical Analysis for 0QW0 - Argen-X
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 351.45 | 1.21% | 4.20 |
Earnings due: May 9
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Gapped Up | Strength | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 1.21% | |
Narrow Range Bar | Range Contraction | 1.21% | |
Gapped Down | Weakness | 1.21% | |
Narrow Range Bar | Range Contraction | 0.06% | |
NR7 | Range Contraction | 0.51% | |
Narrow Range Bar | Range Contraction | 0.51% |
Get a Trading Assistant
Argen-X Description
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Classification
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 494.0 |
52 Week Low | 272.4 |
Average Volume | 3,371 |
200-Day Moving Average | 410.82 |
50-Day Moving Average | 359.50 |
20-Day Moving Average | 355.52 |
10-Day Moving Average | 353.79 |
Average True Range | 7.55 |
RSI (14) | 46.52 |
ADX | 10.24 |
+DI | 25.08 |
-DI | 29.21 |
Chandelier Exit (Long, 3 ATRs) | 350.06 |
Chandelier Exit (Short, 3 ATRs) | 347.44 |
Upper Bollinger Bands | 377.01 |
Lower Bollinger Band | 334.04 |
Percent B (%b) | 0.41 |
BandWidth | 12.09 |
MACD Line | -2.67 |
MACD Signal Line | -1.76 |
MACD Histogram | -0.9091 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 354.83 | ||||
Resistance 3 (R3) | 354.45 | 352.95 | 354.26 | ||
Resistance 2 (R2) | 352.95 | 352.09 | 353.14 | 354.07 | |
Resistance 1 (R1) | 352.20 | 351.56 | 352.58 | 352.58 | 353.89 |
Pivot Point | 350.70 | 350.70 | 350.89 | 350.89 | 350.70 |
Support 1 (S1) | 349.95 | 349.84 | 350.33 | 350.33 | 349.01 |
Support 2 (S2) | 348.45 | 349.31 | 348.64 | 348.83 | |
Support 3 (S3) | 347.70 | 348.45 | 348.64 | ||
Support 4 (S4) | 348.08 |